Search

Your search keyword '"Morand-Joubert L"' showing total 293 results
Start Over Author "Morand-Joubert L"
293 results on '"Morand-Joubert L"'

2. Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen.

Author

Dimeglio, Chloé, Raymond, Stéphanie, Nicot, Florence, Jeanne, Nicolas, Carcenac, Romain, Lefebvre, Caroline, Izopet, Jacques, Roussel, C, Guillou-Guillemette, H Le, Alloui, C, Bettinger, D, Pallier, C, Fleury, H, Bellecave, P, Recordon-Pinson, P, Payan, C, Vallet, S, Vabret, A, Dina, J, Henquell, C, Mirand, A, Bouvier-Alias, M, de Rougemont, A, Si-Mohammed, A, Santos, G Dos, Morand, P, Signori-Schmuck, A, Bocket, L, Rogez, S, Andre, P, Tardy, JC, Trabaud, MA, Tamalet, C, Delamare, C, Montes, B, Schvoerer, E, Jeulin, H, Ferré, V, Rodallec, A, Guen, L Le, Cottalorda, J, Guinard, J, Guiguon, A, Descamps, D, Charpentier, C, Visseaux, B, Peytavin, G, Krivine, A, Bouviers-Alias, M, Avettand-Fenoel, V, Marcelin, AG, Calvez, V, Soulié, C, Wirden, M, Morand-Joubert, L, Lambert-Niclot, S, Fofana, D, Delaugerre, C, Chaix, ML, Mahjoub, N, Amiel, C, Schneider, V, Giraudeau, G, Beby-Defaux, A, Brodard, V, Maillard, A, Plantier, JC, Mourez, T, Leoz, M, Chaplain, C, Bourlet, T, Fafi-Kremer, S, Stoll-Keller, F, Schmitt, MP, Barth, H, Yerly, S, Poggi, C, Izopet, J, Raymond, S, Barin, F, Chaillon, A, Marque-Juillet, S, Roque-Afonso, AM, Haïm-Boukobza, S, Flandre, P, Grudé, M, Assoumou, L, and Costagliola, D

Subjects
Clinical Research, Genetics, HIV/AIDS, Infectious Diseases, Infection, Antiretroviral Therapy, Highly Active, Drug Resistance, Viral, Female, Genome, Viral, Genotype, HIV Infections, HIV-1, High-Throughput Nucleotide Sequencing, Humans, Male, Mutation, Rilpivirine, Treatment Outcome, Viral Load, French National Agency for Research on AIDS and Viral Hepatitis (ANRS) AC11 Resistance Study Group, Microbiology, Medical Microbiology, Pharmacology and Pharmaceutical Sciences
Abstract

ObjectivesTo determine how the load of rilpivirine-resistant variants (mutational load) influences the virological response (VR) of HIV-1-infected patients to a rilpivirine-based first-line regimen.Patients and methodsFour hundred and eighty-nine patients infected with HIV-1 whose reverse transcriptase gene had been successfully resistance genotyped using next-generation sequencing were given a first-line regimen containing rilpivirine. Variables associated with the VR at 12 months were identified using a logistic model. The results were used to build a multivariate model for each mutational load threshold and the R2 variations were analysed to identify the mutational load threshold that best predicted the VR.ResultsThe mutational load at baseline was the only variable linked to the VR at 12 months (P  1700 copies/mL and to 50% when the mutational load was > 9000 copies/mL. The threshold of 9000 copies/mL was associated with the VR at 12 months with an OR of 36.7 (95% CI 4.7-285.1). The threshold of 1700 copies/mL was associated with the VR at 12 months with an OR of 7.2 (95% CI 1.4-36.8).ConclusionsThere is quantifiable evidence that determining a mutational load threshold can be used to identify those patients on a first-line regimen containing rilpivirine who are at risk of virological failure. The clinical management of HIV-infected patients can be improved by evaluating the frequency of mutant variants at a threshold of

Published
2019

3. Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

Author

Raymond, Stéphanie, Nicot, Florence, Pallier, Coralie, Bellecave, Pantxika, Maillard, Anne, Trabaud, Mary Anne, Morand-Joubert, Laurence, Rodallec, Audrey, Amiel, Corinne, Mourez, Thomas, Bocket, Laurence, Beby-Defaux, Agnès, Bouvier-Alias, Magali, Lambert-Niclot, Sidonie, Charpentier, Charlotte, Malve, Brice, Mirand, Audrey, Dina, Julia, Le Guillou-Guillemette, Hélène, Marque-Juillet, Stéphanie, Signori-Schmuck, Anne, Barin, Francis, Si-Mohamed, Ali, Fenoel, Véronique Avettand, Roussel, Catherine, Calvez, Vincent, Saune, Karine, Marcelin, Anne Geneviève, Rodriguez, Christophe, Descamps, Diane, Izopet, Jacques, Lagier, E, Roussel, C, Le Guillou-Guillemette, H, Alloui, C, Bettinger, D, Pallier, C, Fleury, H, Reigadas, S, Bellecave, P, Recordon-Pinson, P, Payan, C, Vallet, S, Vabret, A, Dina, J, Henquell, C, Mirand, A, Bouvier-Alias, M, de Rougemont, A, Dos Santos, G, Morand, P, Signori-Schmuck, A, Bocket, L, Rogez, S, Andre, P, Tardy, JC, Trabaud, MA, Tamalet, C, Delamare, C, Montes, B, Schvoerer, E, Ferré, V, André-Garnier, E, Cottalorda, J, Guinard, J, Guiguon, A, Descamps, D, Brun-Vézinet, F, Charpentier, C, Visseaux, B, Peytavin, G, Krivine, A, Si-Mohamed, A, Avettand-Fenoel, V, Marcelin, AG, Calvez, V, Lambert-Niclot, S, Soulié, C, Wirden, M, Morand-Joubert, L, Delaugerre, C, Chaix, ML, Amiel, C, Schneider, V, Giraudeau, G, Defaux, A Beby-, Brodard, V, Maillard, A, Plantier, JC, Chaplain, C, Bourlet, T, Fafi-Kremer, S, Stoll-Keller, F, Schmitt, MP, Barth, H, Yerly, S, Poggi, C, Izopet, J, Raymond, S, and Barin, F

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Immunology, Antimicrobial Resistance, Genetics, HIV/AIDS, Clinical Research, Infectious Diseases, Aetiology, 2.1 Biological and endogenous factors, Infection, Good Health and Well Being, Adult, Drug Resistance, Viral, Female, Genetic Variation, HIV Infections, HIV-1, Humans, Male, Mutation, Rilpivirine, Viral Load, minority resistant variants, rilpivirine, first-line antiretroviral therapy, ultra-deep sequencing, French National Agency for Research on AIDS and Viral Hepatitis (ANRS) AC11 Resistance Study Group, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

BackgroundMinority resistant variants of human immunodeficiency virus type 1 (HIV-1) could influence the virological response to treatment based on nonnucleoside reverse transcriptase inhibitors (NNRTIs). Data on minority rilpivirine-resistant variants are scarce. This study used next-generation sequencing (NGS) to identify patients harboring minority resistant variants to nucleos(t)ide reverse transcriptase inhibitors and NNRTIs and to assess their influence on the virological response (VR).MethodsAll the subjects, 541 HIV-1-infected patients started a first-line regimen containing rilpivirine. VR was defined as a HIV-1 RNA load 20% in 29% of samples. We identified 43 (8.8%) and 36 (7.4%) patients who harbored rilpivirine-resistant variants with a 1% sensitivity threshold according to the French National Agency for Research on AIDS and Viral Hepatitis and Stanford algorithms, respectively. The VR was 96.9% at month 12. Detection of minority rilpivirine resistant variants was not associated with virological failure (VF). Multivariate analysis indicated that VF at month 12 was associated with a CD4 count

Published
2018

4. EE485 Cost-Effectiveness of a 4 Days-a-Week Triple Therapy in Persons Living with HIV: An Ancillary Study of the Anrs 170 Quatuor Noninferiority Trial

Author

Hejblum, G., primary, Daher, S., additional, Moulaire, P., additional, Amat, K.A., additional, Lambert-Niclot, S., additional, Allavena, C., additional, Katlama, C., additional, Lacombe, K., additional, Ponscarme, D., additional, Ghosn, J., additional, Gibowski, S., additional, Alvarez, J.C., additional, Capeau, J., additional, Morand-Joubert, L., additional, Costagliola, D., additional, De Truchis, P., additional, Landman, R., additional, and Assoumou, L., additional

Published
2023
Full Text
View/download PDF

5. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients

Author

Fourati, Slim, Charpentier, Charlotte, Amiel, Corinne, Morand-Joubert, Laurence, Reigadas, Sandrine, Trabaud, Mary-Anne, Delaugerre, Constance, Nicot, Florence, Rodallec, Audrey, Maillard, Anne, Mirand, Audrey, Jeulin, Hélène, Montès, Brigitte, Barin, Francis, Bettinger, Dominique, Le Guillou-Guillemette, Hélène, Vallet, Sophie, Signori-Schmuck, Anne, Descamps, Diane, Calvez, Vincent, Flandre, Philippe, Marcelin, Anne-Genevieve, Lagier, E, Roussel, C, Le Guillou, H, Alloui, C, Bettinger, D, Pallier, C, Fleury, H, Reigadas, S, Bellecave, P, Recordon-Pinson, P, Payan, C, Vallet, S, Vabret, A, Henquell, C, Mirand, A, Bouvier-Alias, M, de Rougemont, A, Dos Santos, G, Morand, P, Signori-Schmuck, A, Bocket, L, Rogez, S, Andre, P, Tardy, JC, Trabaud, MA, Tamalet, C, Delamare, C, Montes, B, Schvoerer, E, Ferre, V, André-Garnier, E, Cottalorda, J, Guinard, J, Guiguon, A, Descamps, D, Brun-Vézinet, F, Charpentier, C, Visseaux, B, Peytavin, G, Krivine, A, Si-Mohamed, A, Avettand-Fenoel, V, Marcelin, AG, Calvez, V, Lambert-Niclot, S, Soulié, C, Wirden, M, Morand-Joubert, L, Delaugerre, C, Chaix, ML, Amiel, C, Schneider, V, Giraudeau, G, Brodard, V, Maillard, A, Plantier, JC, Chaplain, C, Bourlet, T, Fafi-Kremer, S, Stoll-Keller, F, Schmitt, MP, Barth, H, Yerly, S, Poggi, C, Izopet, J, Raymond, S, Barin, F, Chaillon, A, Marque-Juillet, S, Roque-Afonso, AM, Haïm-Boukobza, S, Flandre, P, Grudé, M, Assoumou, L, Costagliola, D, Allegre, T, Schmit, JL, and Chennebault, JM

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Infectious Diseases, Genetics, Aetiology, 2.1 Biological and endogenous factors, Infection, Adult, Anti-HIV Agents, Drug Resistance, Viral, Female, France, HIV Infections, HIV Integrase, HIV Protease, HIV Reverse Transcriptase, HIV-1, Heterocyclic Compounds, 3-Ring, Humans, Male, Middle Aged, Mutant Proteins, Oxazines, Piperazines, Pyridones, Quinolones, Raltegravir Potassium, Sequence Analysis, DNA, integrase, inhibitors, mutations, patterns, ANRS AC11 Resistance Study Group, Microbiology, Pharmacology and Pharmaceutical Sciences, Clinical sciences, Pharmacology and pharmaceutical sciences
Abstract

ObjectivesThe objectives of this study were to determine the prevalence and patterns of resistance to integrase strand transfer inhibitors (INSTIs) in patients experiencing virological failure on raltegravir-based ART and the impact on susceptibility to INSTIs (raltegravir, elvitegravir and dolutegravir).Patients and methodsData were collected from 502 treatment-experienced patients failing a raltegravir-containing regimen in a multicentre study. Reverse transcriptase, protease and integrase were sequenced at failure for each patient. INSTI resistance-associated mutations investigated were those included in the last ANRS genotypic algorithm (v23).ResultsAmong the 502 patients, at failure, median baseline HIV-1 RNA (viral load) was 2.9 log10 copies/mL. Patients had been previously exposed to a median of five NRTIs, one NNRTI and three PIs. Seventy-one percent harboured HIV-1 subtype B and the most frequent non-B subtype was CRF02_AG (13.3%). The most frequent mutations observed were N155H/S (19.1%), Q148G/H/K/R (15.4%) and Y143C/G/H/R/S (6.7%). At failure, viruses were considered as fully susceptible to all INSTIs in 61.0% of cases, whilst 38.6% were considered as resistant to raltegravir, 34.9% to elvitegravir and 13.9% to dolutegravir. In the case of resistance to raltegravir, viruses were considered as susceptible to elvitegravir in 11% and to dolutegravir in 64% of cases. High HIV-1 viral load at failure (P

Published
2015

6. Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma

Author

Soulie, C, Descamps, D, Grude, M, Schneider, V, Trabaud, M-A, Morand-Joubert, L, Delaugerre, C, Montes, B, Barin, F, Ferre, V, Raymond, S, Jeulin, H, Alloui, C, Yerly, S, Pallier, C, Reigadas, S, Signori-Schmuck, A, Guigon, A, Fafi-Kremer, S, Haim-Boukobza, S, Mirand, A, Maillard, A, Vallet, S, Roussel, C, Assoumou, L, Calvez, V, Flandre, P, Marcelin, A-G, Lagier, E, Le Guillou, H, Bettinger, D, Fleury, H, Bellecave, P, Recordon-Pinson, P, Payan, C, Vabret, A, Henquell, C, Bouvier-Alias, M, de Rougemont, A, Dos Santos, G, Morand, P, Bocket, L, Rogez, S, Andre, P, Tardy, JC, Trabaud, MA, Tamalet, C, Delamare, C, Schvoerer, E, Andre-Garnier, E, Cottalorda, J, Guinard, J, Guiguon, A, Brun-Vezinet, F, Charpentier, C, Visseaux, B, Peytavin, G, Krivine, A, Si-Mohamed, A, Avettand-Fenoel, V, Marcelin, AG, Lambert-Niclot, S, Wirden, M, Chaix, ML, Amiel, C, Giraudeau, G, Brodard, V, Plantier, JC, Chaplain, C, Bourlet, T, Stoll-Keller, F, Schmitt, MP, Barth, H, Poggi, C, Izopet, J, Chaillon, A, Marque-Juillet, S, and Roque-Afonso, AM

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, HIV/AIDS, Infectious Diseases, Antimicrobial Resistance, Genetics, Clinical Research, Neurosciences, Infection, Adult, Anti-HIV Agents, Antiretroviral Therapy, Highly Active, Drug Resistance, Viral, Female, Genotype, HIV Infections, HIV-1, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Mutation, Nervous System Diseases, Viral Load, ANRS Resistance AC11 Group, ARV, CSF, HIV, resistance, Microbiology, Pharmacology and Pharmaceutical Sciences, Clinical sciences, Pharmacology and pharmaceutical sciences
Abstract

OBJECTIVES: The neurological disorders in HIV-1-infected patients remain prevalent. The HIV-1 resistance in plasma and CSF was compared in patients with neurological disorders in a multicentre study. METHODS: Blood and CSF samples were collected at time of neurological disorders for 244 patients. The viral loads were >50 copies/mL in both compartments and bulk genotypic tests were realized. RESULTS: On 244 patients, 89 and 155 were antiretroviral (ARV) naive and ARV treated, respectively. In ARV-naive patients, detection of mutations in CSF and not in plasma were reported for the reverse transcriptase (RT) gene in 2/89 patients (2.2%) and for the protease gene in 1/89 patients (1.1%). In ARV-treated patients, 19/152 (12.5%) patients had HIV-1 mutations only in the CSF for the RT gene and 30/151 (19.8%) for the protease gene. Two mutations appeared statistically more prevalent in the CSF than in plasma: M41L (P=0.0455) and T215Y (P=0.0455). CONCLUSIONS: In most cases, resistance mutations were present and similar in both studied compartments. However, in 3.4% of ARV-naive and 8.8% of ARV-treated patients, the virus was more resistant in CSF than in plasma. These results support the need for genotypic resistance testing when lumbar puncture is performed.

Published
2015

7. Prevalence of baseline virological risk factors of increased virological failure to CAB+RPV among ARV-naive patients

Author

Charpentier, C., Storto, A., Soulie, C., Ferre, VM., Wirden, M., Joly, V., Lambert-Niclot, S., Morand-Joubert, L., Landman, R., Lacombe, K., Katlama, C., Ghosn, J., Marcelin, A-G., Calvez, V., and Descamps, D.

Subjects
Gene mutations -- Health aspects, Antiviral agents -- Patient outcomes, Drug resistance -- Genetic aspects, Genetic polymorphisms -- Health aspects, HIV infection -- Genetic aspects -- Development and progression -- Drug therapy, Health
Abstract

Background: Multivariable baseline factor analysis across CAB+RPV phase 3 studies recently showed that HIV-1 subtypes A6/A1, characterized by the L74I integrase (IN) polymorphism, and presence of RPV resistance-associated mutations (RAM), [...]

Published
2021
Full Text
View/download PDF

9. First cases of Omicron in France are exhibiting mild symptoms, November 2021–January 2022

Author

Maisa, A., primary, Spaccaferri, G., additional, Fournier, L., additional, Schaeffer, J., additional, Deniau, J., additional, Rolland, P., additional, Coignard, B., additional, Andrieu, A., additional, Broustal, O., additional, Chene, S., additional, Chent, S., additional, Fougère, E., additional, Gbaguidi, G., additional, Hamidouche, M., additional, Lamy, A., additional, Mano, Q., additional, Mastrovito, B., additional, Mercier, A., additional, Modenesi, G., additional, Picard, G., additional, Prudhomme, J., additional, Rapilly, F., additional, Riondel, A., additional, Rivière, M., additional, Villegas Ramirez, B., additional, Zhu-Soubise, A., additional, Zurbaran, M., additional, Amzert, A., additional, Andreoletti, L., additional, Bal, A., additional, Beaurepere, R., additional, Behillil, S., additional, Belec, L., additional, Bernard, C., additional, Bocket, L., additional, Bouri, L., additional, Bourlet, T., additional, Bressollette-Bodin, C., additional, Brichler, S., additional, Brugerolles, C., additional, Cado, S., additional, Calvez, V., additional, Capron, N., additional, Castelain, S., additional, Castro-Alvarez, J., additional, Chaix, M.-L., additional, Charpentier, C., additional, Che, D., additional, Chillou, C., additional, Colson, P., additional, Coudene, P., additional, Crinquette, A., additional, De Rougemont, A., additional, Delagrèverie, H., additional, Delamare, C., additional, Denecker-Berardino, T., additional, Descamps, D., additional, Desroches, M., additional, Destras, G., additional, Dos Santos, G., additional, Ducancelle, A., additional, Ducreux, S., additional, Duret, T., additional, Enouf, V., additional, Fafi-Kremer, S., additional, Felici, C., additional, Fourati, S., additional, Fournier, P.-E., additional, Gaudy, C., additional, Germain, H., additional, Giordanengo, V., additional, Gorge, O., additional, Haim-Boukobza, S., additional, Henquell, C., additional, Holstein, A., additional, Houhamdi, L., additional, Izopet, J., additional, Jacomo, V., additional, Jacques, A., additional, Jaffar-Bandjee, M.-C., additional, Jimenez, M., additional, Josset, L., additional, Kemeny, S., additional, Lafon, M.-E., additional, Le Bars, A., additional, Le Corguille, G., additional, Lepiller, Q., additional, Levasseur, A., additional, Leveque, N., additional, Lina, B., additional, Madelaine, C., additional, Malabat, C., additional, Marque-Juillet, S., additional, Martin-Dunavit, T., additional, Mavingui, P., additional, Merens, A., additional, Messak, I., additional, Morand-Joubert, L., additional, Naudot, X., additional, Neybecker, P., additional, Pawlotsky, J.-M., additional, Pilorge, L., additional, Plantier, J.-C., additional, Poggi, C., additional, Pretet, M., additional, Ragot, C., additional, Raoul, H., additional, Rogez, S., additional, Roque-Afonso, A.-M., additional, Roquebert, B., additional, Rousset, D., additional, Rozenberg, F., additional, Sagot, C., additional, Sahnoune, S., additional, Salgado, D., additional, Sand, O., additional, Saudemont, C., additional, Schvoerer, E., additional, Simon-Loriere, E., additional, Stephan, R., additional, Sudour, J., additional, Thibault, V., additional, Tuaillon, E., additional, Vabret, A., additional, Vallee, E., additional, Van Der Werf, S., additional, Van Helden, J., additional, Verdurme, L., additional, Vignola, A., additional, Wilkinson, D., additional, and Yazdanpanah, Y., additional

Published
2022
Full Text
View/download PDF

10. First cases of Omicron in France are exhibiting mild symptoms, November 2021–January 2022

Author

Andrieu, A., Broustal, O., Chene, S., Chent, S., Fougère, E., Gbaguidi, G., Hamidouche, M., Lamy, A., Mano, Q., Mastrovito, B., Mercier, A., Modenesi, G., Picard, G., Prudhomme, J., Rapilly, F., Riondel, A., Rivière, M., Villegas Ramirez, B., Zhu-Soubise, A., Zurbaran, M., Amzert, A., Andreoletti, L., Bal, A., Beaurepere, R., Behillil, S., Belec, L., Bernard, C., Bocket, L., Bouri, L., Bourlet, T., Bressollette-Bodin, C., Brichler, S., Brugerolles, C., Cado, S., Calvez, V., Capron, N., Castelain, S., Castro-Alvarez, J., Chaix, M.-L., Charpentier, C., Che, D., Chillou, C., Colson, P., Coudene, P., Crinquette, A., De Rougemont, A., Delagrèverie, H., Delamare, C., Denecker-Berardino, T., Descamps, D., Desroches, M., Destras, G., Dos Santos, G., Ducancelle, A., Ducreux, S., Duret, T., Enouf, V., Fafi-Kremer, S., Felici, C., Fourati, S., Fournier, P.-E., Gaudy, C., Germain, H., Giordanengo, V., Gorge, O., Haim-Boukobza, S., Henquell, C., Holstein, A., Houhamdi, L., Izopet, J., Jacomo, V., Jacques, A., Jaffar-Bandjee, M.-C., Jimenez, M., Josset, L., Kemeny, S., Lafon, M.-E., Le Bars, A., Le Corguille, G., Lepiller, Q., Levasseur, A., Leveque, N., Lina, B., Madelaine, C., Malabat, C., Marque-Juillet, S., Martin-Dunavit, T., Mavingui, P., Merens, A., Messak, I., Morand-Joubert, L., Naudot, X., Neybecker, P., Pawlotsky, J.-M., Pilorge, L., Plantier, J.-C., Poggi, C., Pretet, M., Ragot, C., Raoul, H., Rogez, S., Roque-Afonso, A.-M., Roquebert, B., Rousset, D., Rozenberg, F., Sagot, C., Sahnoune, S., Salgado, D., Sand, O., Saudemont, C., Schvoerer, E., Simon-Loriere, E., Stephan, R., Sudour, J., Thibault, V., Tuaillon, E., Vabret, A., Vallee, E., Van Der Werf, S., Van Helden, J., Verdurme, L., Vignola, A., Wilkinson, D., Yazdanpanah, Y., Maisa, A., Spaccaferri, G., Fournier, L., Schaeffer, J., Deniau, J., Rolland, P., and Coignard, B.

Published
2022
Full Text
View/download PDF

12. High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers

Author

Palich, R., primary, Veyri, M., additional, Vozy, A., additional, Marot, S., additional, Gligorov, J., additional, Benderra, M.-A., additional, Maingon, P., additional, Morand-Joubert, L., additional, Adjoutah, Z., additional, Marcelin, A.-G., additional, Spano, J.-P., additional, and Barrière, J., additional

Published
2021
Full Text
View/download PDF

13. Virological failure of patients on maraviroc-based antiretroviral therapy

Author

Raymond, Stéphanie, Maillard, Anne, Amiel, Corinne, Peytavin, Gilles, Trabaud, Mary Anne, Desbois, Delphine, Bellecave, Pantxika, Delaugerre, Constance, Soulie, Cathia, Marcelin, Anne Geneviève, Descamps, Diane, Izopet, Jacques, Reigadas, S., Bellecave, P., Pinson-Recordon, P., Fleury, H., Masquelier, B., Signori-Schmuck, A., Morand, P., Bocket, L., Mouna, L., André, P., Tardy, J. C., Trabaud, M. A., Descamps, D., Charpentier, C., Peytavin, G., Brun-Vézinet, F., Haim-Boukobza, S., Roques, A. M., Soulié, C., Lambert-Niclot, S., Malet, I., Wirden, M., Fourati, S., Marcelin, A. G., Calvez, V., Flandre, P., Assoumou, L., Costagliola, D., Morand-Joubert, L., Delaugerre, C., Schneider, V., Amiel, C., Giraudeau, G., Maillard, A., Nicot, F., and Izopet, J.

Published
2015
Full Text
View/download PDF

16. Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial)

Author

Gallien, Sébastien, Journot, Valérie, Rozenbaum, Willy, Yéni, Patrick, Morlat, Philippe, Poizot-Martin, Isabelle, Reynes, Jacques, Reliquet, Véronique, Leclercq, Pascale, Simon, François, Chêne, Geneviève, Molina, Jean-Michel, Molina, J.-M., Chêne, G., Rancinan, C., Collin, F., Journot, V., Ferchal, F., Morand-Joubert, L., Palmer, P., Charrois, A., Molina, J.-M., Chêne, G., Journot, V., Rancinan, C., Madelaine, I., Morlat, P., Rozenbaum, W., Sereni, D., Vilde, J. L., Ferchal, F., Morand-Joubert, L., Poizot-Martin, I., Rosenthal, E., Raffi, F., and Reynes, J.

Published
2011
Full Text
View/download PDF

18. National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001–2011

Author

Descamps, Diane, Assoumou, Lambert, Chaix, Marie-Laure, Chaillon, Antoine, Pakianather, Sophie, de Rougemont, Alexis, Storto, Alexandre, Dos Santos, Georges, Krivine, Anne, Delaugerre, Constance, Montes, Brigitte, Izopet, Jacques, Charpentier, Charlotte, Wirden, Marc, Maillard, Anne, Morand-Joubert, Laurence, Pallier, Coralie, Plantier, Jean-Christophe, Guinard, Jérôme, Tamalet, Catherine, Cottalorda, Jacqueline, Marcelin, Anne-Geneviève, Desbois, Delphine, Henquell, Cecile, Calvez, Vincent, Brun-Vézinet, Françoise, Masquelier, Bernard, Costagliola, Dominique, Lagier, E., Roussel, C., Le Guillou-Guillemette, H., Alloui, C., Bettinger, D., Anies, G., Reigadas, S., Bellecave, P., Pinson-Recordon, P., Fleury, H., Masquelier, B., Vallet, S., Leroux, M., Dina, J., Vabret, A., Poveda, J. D., Mirand, A., Henquell, C., Bouvier-Alias, M., Noel, C., De Rougemont, A., Dos Santos, G., Yerly, S., Gaille, C., Caveng, W., Chapalay, S., Calmy, A., Signori-Schmuck, A., Morand, P., Pallier, C., Bocket, L., Mouna, L., Ranger-Rogez, S., André, P., Tardy, J. C., Trabaud, M. A., Tamalet, C., Delamare, C., Montes, B., Schvoerer, E., André-Garnier, E., Férré, V., Cottalorda, J., Guigon, A., Guinard, J., Descamps, D., Charpentier, C., Peytavin, G., Brun-Vézinet, F., Haim-Boukobza, S., Roques, A. M., Soulié, C., Lambert-Niclot, S., Malet, I., Wirden, M., Fourati, S., Marcelin, A. G., Calvez, V., Flandre, P., Assoumou, L., Costagliola, D., Morand-Joubert, L., Delaugerre, C., Schneider, V., Amiel, C., Giraudeau, G., Maillard, A., Plantier, J. C., Fafi-Kremer, S., Schmitt, M. P., Raymond, S., Izopet, J., Chaillon, A., Barin, F., and Marque Juillet, S.

Published
2013
Full Text
View/download PDF

20. HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes

Author

Reigadas, S., Marcelin, A. G., Houssaïni, A., Yerly, S., Descamps, D., Plantier, J. C., Ruffault, A., Amiel, C., Trabaud, M. A., Flandre, Philippe, Fleury, H., Masquelier, B., Roussel, C., Alloui, C., Leguillou-Guillemette, H., Bettinger, D., Pallier, C., Descamps, D., Brun-Vezinet, F., Peytavin, G., Masquelier, B., Pinson, P., Reigadas, S., Vallet, S., Poveda, J. D., Mirand, A., Krivine, A., Auvray, C., de Rougemont, A., Yerly, S., Signori-Schmuck, A., Bocket, L., Rogez, S., Tamalet, C., Schneider, V., Amiel, C., Bouvier-Alias, M., Montes, B., Schvoerer, E., Ferré, V., Chaix, M. L., Guinard, J., Haim-Boukobza, S., Soulié, C., Marcelin, A. G., Flandre, P., Assoumou, L., Calvez, V., Maillard, A., Morand-Joubert, L., Chaplain, C., Delaugerre, C., Bourlet, T., Bertsch, S., Plantier, J. C., Raymond, S., and Marque-Juillet, S.

Published
2013
Full Text
View/download PDF

21. Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study

Author

Valantin, M. A., Lambert-Niclot, S., Flandre, P., Morand-Joubert, L., Cabiè, A., Meynard, J. L., Ponscarme, D., Ajana, F., Slama, L., Curjol, A., Cuzin, L., Schneider, L., Taburet, A. M., Marcelin, A. G., Katlama, C., Katlama, C., Valantin, M. A., Duvivier, C., Flandre, P., Calvez, V., Marcelin, A. G., Peytavin, G., Taburet, A. M., Katlama, C., Duvivier, C., Valantin, M. A., Calvez, V., Marcelin, A. G., Peytavin, G., Kolta, S., Flandre, P., Costagliola, D., Genin, M., Commoy, M.-J., Taburet, A. M., LʼHenaff, M., Chéret, A., Raffi, F., Garaffo, R., Descamps, D., and Chêne, G.

Published
2012
Full Text
View/download PDF

22. Improved V3 genotyping with duplicate PCR amplification for determining HIV-1 tropism

Author

Raymond, Stéphanie, Recordon-Pinson, Patricia, Saliou, Adrien, Delobel, Pierre, Nicot, Florence, Descamps, Diane, Marcelin, Anne-Geneviève, Flandre, Philippe, Calvez, Vincent, Masquelier, Bernard, Izopet, Jacques, Recordon-Pinson, P., Fleury, H., Masquelier, B., Vabret, A., Pallier, C., Lazrek, M, André, P., Tardy, J. C., Trabaud, M. A., Tamalet, C., Montes, B., Segondy, M., Ferré, V., Cottalorda, J., Macé, M., Descamps, D., Brun-Vézinet, F., Si-Mohammed, A., Charpentier, C., Desbois, D., Dussaix, E., Marcelin, A. G., Soulié, C., Calvez, V., Flandre, F., Morand-Joubert, L., Amiel, C., Schneider, V., Maillard, A., Ruffault, A., Izopet, J., Nicot, F., Delobel, P., and Raymond, S.

Published
2011
Full Text
View/download PDF

24. Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France

Author

Descamps, Diane, Chaix, Marie-Laure, Montes, Brigitte, Pakianather, Sophie, Charpentier, Charlotte, Storto, Alexandre, Barin, Francis, Dos Santos, Georges, Krivine, Anne, Delaugerre, Constance, Izopet, Jacques, Marcelin, Anne-Geneviève, Maillard, Anne, Morand-Joubert, Laurence, Pallier, Coralie, Plantier, Jean-Christophe, Tamalet, Catherine, Cottalorda, Jacqueline, Desbois, Delphine, Calvez, Vincent, Brun-Vezinet, Françoise, Masquelier, Bernard, Costagliola, Dominique, Alloui, C., Bettinger, D., Anies, G., Masquelier, B., Vallet, S., Henquell, C., Bouvier-Alias, M., DosSantos, G., Signori-Schmuck, A., Rogez, S., André, P., Tardy, J. C., Trabaud, M. A., Tamalet, C., Montes, B., Cottalorda, J., Descamps, D., Brun-Vézinet, F., Charpentier, C., Chaix, M. L., Desbois, D., Fourati, S., Marcelin, A. G., Calvez, V., Flandre, P., Morand-Joubert, L., Delaugerre, C., Ruffault, A., Maillard, A., Plantier, J. C., Bourlet, T., Saoudin, H., Izopet, J., and Barin, F.

Published
2010
Full Text
View/download PDF

32. HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes

Author

Reigadas, S., Marcelin, A. G., Houssaïni, A., Yerly, S., Descamps, D., Plantier, J. C., Ruffault, A., Amiel, C., Trabaud, M. A., Flandre, Philippe, Fleury, H., Masquelier, B., Roussel, C., Alloui, C., Leguillou-Guillemette, H., Bettinger, D., Pallier, C., Brun-Vezinet, F., Peytavin, G., Pinson, P., Vallet, S., Poveda, J. D., Mirand, A., Krivine, A., Auvray, C., de Rougemont, A., Signori-Schmuck, A., Bocket, L., Rogez, S., Tamalet, C., Schneider, V., Bouvier-Alias, M., Montes, B., Schvoerer, E., Ferré, V., Chaix, M. L., Guinard, J., Haim-Boukobza, S., Soulié, C., Flandre, P., Assoumou, L., Calvez, V., Maillard, A., Morand-Joubert, L., Chaplain, C., Delaugerre, C., Bourlet, T., Bertsch, S., Raymond, S., and Marque-Juillet, S.

Published
2017

33. Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma

Author

Soulie, Cathia, Descamps, Diane, Grudé, Maxime, Schneider, Véronique, Trabaud, Mary-Anne, Morand-Joubert, Laurence, Delaugerre, Constance, Montes, Brigitte, Barin, Francis, Ferre, Virginie, Raymond, Stéphanie, Jeulin, Hélène, Alloui, Chakib, Yerly, Sabine, Pallier, Coralie, Reigadas, Sandrine, Signori-Schmuck, Anne, Guigon, Aurélie, Fafi-Kremer, Samira, Haïm-Boukobza, Stéphanie, Mirand, Audrey, Maillard, Anne, Vallet, Sophie, Roussel, Catherine, Assoumou, Lambert, Calvez, Vincent, Flandre, Philippe, Marcelin, Anne-Geneviève, Lagier, E., Roussel, C., Le Guillou, H., Alloui, C., Bettinger, D., Pallier, C., Fleury, H., Reigadas, S., Bellecave, P., Recordon-Pinson, P., Payan, C., Vallet, S., Vabret, A., Henquell, C., Mirand, A., Bouvier-Alias, M., de Rougemont, A., Dos Santos, G., Morand, P., Signori-Schmuck, A., Bocket, L., Rogez, S., Andre, P., Tardy, J.C., Trabaud, M.A., Tamalet, C., Delamare, C., Montes, B., Schvoerer, E., Ferre, V., André-Garnier, E., Cottalorda, J., Guinard, J., Guiguon, A., Descamps, D., Brun-Vézinet, F., Charpentier, C., Visseaux, B., Peytavin, G., Krivine, A., Si-Mohamed, A., Avettand-Fenoel, V., Marcelin, A.G., Calvez, V., Lambert-Niclot, S., Soulié, C., Wirden, M., Morand-Joubert, L., Delaugerre, C., Chaix, M.L., Amiel, C., Schneider, V., Giraudeau, G., Brodard, V., Maillard, A., Plantier, J.C., Chaplain, C., Bourlet, T., Fafi-Kremer, S., Stoll-Keller, F., Schmitt, M.P., Barth, H., Yerly, S., Poggi, C., Izopet, J., Raymond, S., Barin, F., Chaillon, A., Marque-Juillet, S., Roque-Afonso, A.M., Haïm-Boukobza, S., Flandre, P., Grudé, M., Assoumou, L., Costagliola, D., Allegre, T., Schmit, J.L., Chennebault, J. M., Bouchaud, O., Magy-Bertrand, N., Delfraissy, J.F., Dupon, M., Morlat, P., Neau, D., Ansart, S., Jaffuel, S., Verdon, R., Jacomet, C., Lévy, Y., Dominguez, S., Chavanet, P., Piroth, L., Cabié, A., Leclercq, P., Ajana, F., Cheret, A., Weinbreck, P., Cotte, L., Poizot-Martin, I., Ravaud, I., Christian, B., Truchetet, F., Grandidier, M., Reynes, J., May, T., Goehringer, F., Raffi, F., Dellamonica, P., Prazuck, T., Hocqueloux, L., Yéni, P., Landman, R., Launay, O., Weiss, L., Viard, J.P., Katlama, C., Simon, A., Girard, P.M., Meynard, J.L., Molina, J.M., Pialoux, G., Hoen, B., Goeger-Sow, M.T., Lamaury, I., Beaucaire, G., Jaussaud, R., Rouger, C., Michelet, C., Borsa-Lebas, F., Caron, F., Khuong, M.A., Lucht, F., Rey, D., Calmy, A., Marchou, B., Gras, G., Greder-Belan, A., Vittecoq, D., and Teicher, E.

Subjects
virus diseases
Abstract

Objectives The neurological disorders in HIV-1-infected patients remain prevalent. The HIV-1 resistance in plasma and CSF was compared in patients with neurological disorders in a multicentre study. Methods Blood and CSF samples were collected at time of neurological disorders for 244 patients. The viral loads were >50 copies/mL in both compartments and bulk genotypic tests were realized. Results On 244 patients, 89 and 155 were antiretroviral (ARV) naive and ARV treated, respectively. In ARV-naive patients, detection of mutations in CSF and not in plasma were reported for the reverse transcriptase (RT) gene in 2/89 patients (2.2%) and for the protease gene in 1/89 patients (1.1%). In ARV-treated patients, 19/152 (12.5%) patients had HIV-1 mutations only in the CSF for the RT gene and 30/151 (19.8%) for the protease gene. Two mutations appeared statistically more prevalent in the CSF than in plasma: M41L (P = 0.0455) and T215Y (P = 0.0455). Conclusions In most cases, resistance mutations were present and similar in both studied compartments. However, in 3.4% of ARV-naive and 8.8% of ARV-treated patients, the virus was more resistant in CSF than in plasma. These results support the need for genotypic resistance testing when lumbar puncture is performed

Published
2017

34. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study

Author

Assoumou, L., Charpentier, C., Recordon-Pinson, P., Grude, M., Pallier, C., Morand-Joubert, L., Fafi-Kremer, S., Krivine, A., Montes, B, Ferre, V., Bouvier-Alias, M., Plantier, C., Izopet, J., Trabaud, M., Yerly, S., Dufayard, J., Alloui, C., Courdavault, L., Le Guillou-Guillemette, H., Maillard, A., Amiel, C., Vabret, A., Roussel, C., Vallet, S., Guinard, J., Mirand, A., Beby-Defaux, A., Barin, F., Allardet-Servent, A., Ait-Namane, R., Wirden, M., Delaugerre, C., Calvez, V., Chaix, L., Descamps, D., Reigadas, S., Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neuroimagerie cognitive (LCogn), Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Virologie [Strasbourg], AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre hospitalier universitaire de Nantes (CHU Nantes), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Equipe de Recherche en Physico-Chimie et Biotechnologie (ERPCB), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU), Laboratoire de Virologie Humaine et Moléculaire [Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), UR 0420 - Station de pathologie végétale, Laboratoire de pathologie forestière, Institut National de la Recherche Agronomique (INRA)-Institut National de la Recherche Agronomique (INRA), Laboratoire Universitaire de Biodiversité et Ecologie Microbienne (LUBEM), Université de Brest (UBO), CHU Orléans, CHU Clermont-Ferrand, Laboratoire Microorganismes : Génome et Environnement (LMGE), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Service de microbiologie [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Microbiologie cellulaire et moléculaire et pathogénicité (MCMP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service de Virologie [CHU Bichat], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Hôpital Cochin [AP-HP], CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Groupe de Recherche sur l'Adaptation Microbienne (GRAM 2.0), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Département de microbiologie [CHU Rouen], CHU Rouen, Laboratoire de Virologie [Toulouse], CHU Toulouse [Toulouse], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Hôpitaux Universitaires de Genève (HUG), Hôpital l'Archet, Hôpital Avicenne [AP-HP], Centre Hospitalier Victor Dupouy, CHU Pontchaillou [Rennes], CHU Tenon [AP-HP], CHU Amiens-Picardie, Centre Hospitalier Régional d'Orléans (CHRO), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Génétique et Ecologie des Virus, Génétique des Virus et Pathogénèse des Maladies Virales, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hopital Saint-Louis [AP-HP] (AP-HP), Centre d'Etudes Lasers Intenses et Applications (CELIA), Université de Bordeaux (UB)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Microbiologie Fondamentale et Pathogénicité (MFP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire Virologie [CHU Toulouse], Institut Fédératif de Biologie (IFB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Université de Caen Normandie (UNICAEN), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Bordeaux (UB), CHU Cochin [AP-HP], T1, Laboratoire Matériaux Optiques, Photonique et Systèmes (LMOPS), CentraleSupélec-Université de Lorraine (UL)-CentraleSupélec-Université de Lorraine (UL), CHU Tenon [APHP], Station de recherches sur la vache laitière, Institut National de la Recherche Agronomique (INRA), Laboratoire Microorganismes : Génome et Environnement - Clermont Auvergne (LMGE), Université Clermont Auvergne (UCA)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7), and CHU Pitié-Salpêtrière [APHP]

Subjects
0301 basic medicine, Microbiology (medical), Adult, Male, Genes, Viral, Genotype, Anti-HIV Agents, 030106 microbiology, HIV Infections, HIV Integrase, [SDV.MP.PRO]Life Sciences [q-bio]/Microbiology and Parasitology/Protistology, 03 medical and health sciences, 0302 clinical medicine, Drug Resistance, Multiple, Viral, HIV Protease, Antiretroviral Therapy, Highly Active, Humans, Pharmacology (medical), 030212 general & internal medicine, Treatment Failure, ComputingMilieux_MISCELLANEOUS, Pharmacology, Sequence Analysis, DNA, Middle Aged, Viral Load, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, HIV Reverse Transcriptase, 3. Good health, Infectious Diseases, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, HIV-1, RNA, Viral, Reverse Transcriptase Inhibitors, Female, France, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Surveillance of HIV-1 resistance in treated patients with a detectable viral load (VL) is important to monitor, in order to assess the risk of spread of resistant viruses and to determine the proportion of patients who need new antiretroviral drugs with minimal cross-resistance.The HIV-1 protease and reverse transcriptase (RT) and integrase genes were sequenced in plasma samples from 782 consecutive patients on failing antiretroviral regimens, seen in 37 specialized centres in 2014. The genotyping results were interpreted using the ANRS v24 algorithm. Prevalence rates were compared with those obtained during a similar survey conducted in 2009.The protease and RT sequences were obtained in 566 patients, and the integrase sequence in 382 patients. Sequencing was successful in 60%, 78%, 78% and 87% of patients with VLs of 51-200, 201-500, 501-1000 and1000 copies/mL, respectively. Resistance to at least one antiretroviral drug was detected in 56.3% of samples. Respectively, 3.9%, 8.7%, 1.5% and 3.4% of patients harboured viruses that were resistant to any NRTI, NNRTI, PI and integrase inhibitor (INI). Resistance rates were lower in 2014 than in 2009. Resistance was detected in 48.5% of samples from patients with a VL between 51 and 200 copies/mL.In France in 2014, 90.0% of patients in AIDS care centres were receiving antiretroviral drugs and 12.0% of them had VLs50 copies/mL. Therefore, this study suggests that 6.7% of treated patients in France might transmit resistant strains. Resistance testing may be warranted in all treated patients with VL 50 copies/mL.

Published
2017

36. Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing

Author

Nguyen, T, primary, Fofana, D B, additional, Lê, M P, additional, Charpentier, C, additional, Peytavin, G, additional, Wirden, M, additional, Lambert-Niclot, S, additional, Desire, N, additional, Grude, M, additional, Morand-Joubert, L, additional, Flandre, P, additional, Katlama, C, additional, Descamps, D, additional, Calvez, V, additional, Todesco, E, additional, and Marcelin, A G, additional

Published
2018
Full Text
View/download PDF

43. Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy

Author

Lambert-Niclot, S., primary, Charpentier, C., additional, Storto, A., additional, Fofana, D., additional, Soulie, C., additional, Fourati, S., additional, Wirden, M., additional, Morand-Joubert, L., additional, Masquelier, B., additional, Flandre, P., additional, Calvez, V., additional, Descamps, D., additional, and Marcelin, A. G., additional

Published
2013
Full Text
View/download PDF

44. Effectiveness of ritonavir-boosted protease inhibitor monotherapy in routine practice

Author

Fonquernie, L, Lefebvre, B, Valin, N, Morand?Joubert, L, Boyd, A, and Meynard, J

Subjects
Ritonavir -- Testing, Viremia -- Measurement, HIV patients -- Care and treatment, AIDS treatment -- Patient outcomes, Health
Abstract

Background: Recent trials have shown the potential benefits of ritonavir‐boosted protease inhibitor (PI/r) monotherapy. As this alternative strategy has recently been included in European HIV treatment guidelines, its effectiveness needs to be assessed in routine practice. Methods: From 1st January to 31 December 2011, we identified all patients receiving a current PI/r monotherapy at a university‐based hospital setting using the Diamm database system. Antiretroviral‐naïve patients who directly initiated PI/r monotherapy were excluded. Patients who continued PI/r monotherapy after ending participation in a clinical trial were also included. We performed a retrospective, descriptive analysis of demographic, clinical and therapeutic characteristics of these patients. For biological variables, the last available value in 2011 was retained. Results: In 2011, among 3140 antiretroviral‐treated patients in our department, 107 (3.4%) received PI/r monotherapy (lopinavir/r n = 58, darunavir/r n= 49). Of them, 30 (28%) started during 2011 and 31 (29%) continued after a prior trial. Two patients switched to DRV/r due to intolerance. Eighty‐eight percent were male and median age at initiation was 45 years. The median time from starting multitherapy and switching to monotherapy was 30 months (range 2–117). At PI/r monotherapy initiation, median CD4 count was 567 cells/mm[sup.3] and HIV RNA was below 50 copies/mL in 90% of patients. The median duration under PI/r monotherapy was 25.4 months (range 0.5–93). At the end of follow‐up, median CD4 count was 643 cells/mm[sup.3] and HIV RNA was below 50 copies/mL in 89% of cases. During 2011, 11 patients discontinued PI/r monotherapy, of whom 8 presented viral rebound. Only one patient exhibited major protease mutations. All these 8 patients achieved an undetectable viral load 3 months after therapeutic intensification. Conclusion: This descriptive analysis shows that PI/r monotherapy in routine practice could be considered as an alternative and successful maintenance strategy, especially among patients who achieved an undetectable viral load while undergoing prior multitherapy., Reference World Health Organization. Use of efavirenz during pregnancy: a public health perspective [Internet]; 2012 [cited 2012 Jul]. Available from: http://www.who.int/hiv/pub/treatment2/efavirenz/en/index.html#. DOI: [...]

Published
2012
Full Text
View/download PDF

46. Short‐course intensification with enfuvirtide in virologic failure: impact on intracellular HIV reservoir and on viral tropism (INNOVE study)

Author

Ghosn, J, Delaugerre, C, Pinta, A, Pierre, N, Etienne, D, Raffi, F, and Morand?Joubert, L

Subjects
Virus latency -- Physiological aspects, Tropisms -- Physiological aspects, Enfuvirtide -- Patient outcomes -- Testing -- Dosage and administration, HIV infection -- Drug therapy -- Patient outcomes, Health
Abstract

7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, Background Overall, studies of ART intensification in suppressed patients showed no reduction in HIV reservoir, as assessed by proviral DNA. Limited data about impact of ART intensification are available for [...]

Published
2010
Full Text
View/download PDF

47. Risk factors for raltegravir resistance development in clinical practice

Author

Malet, I., primary, Fourati, S., additional, Morand-Joubert, L., additional, Flandre, P., additional, Wirden, M., additional, Haim-Boukobza, S., additional, Sayon, S., additional, Pattery, T., additional, Simon, A., additional, Katlama, C., additional, Girard, P.-M., additional, Calvez, V., additional, and Marcelin, A.-G., additional

Published
2012
Full Text
View/download PDF

49. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype

Author

Malet, I., primary, Fourati, S., additional, Charpentier, C., additional, Morand-Joubert, L., additional, Armenia, D., additional, Wirden, M., additional, Sayon, S., additional, Van Houtte, M., additional, Ceccherini-Silberstein, F., additional, Brun-Vezinet, F., additional, Perno, C.-F., additional, Descamps, D., additional, Capt, A., additional, Calvez, V., additional, and Marcelin, A.-G., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results